#MAT2A - Twitter Hashtag

9 months ago

Epigenetics Update - MAT2A promotes atherosclerotic plaque vulnerability by mediating epigenetic reprogramming of macrophages https://t.co/OPlYTGGijw #Epigenetics #MAT2A #Atherosclerosis --- High-resolution insights without cell sorting; https://t.co/WmSYDGXnzb

EpigenomeTech's tweet photo. Epigenetics Update - MAT2A promotes atherosclerotic plaque vulnerability by mediating epigenetic reprogramming of macrophages https://t.co/OPlYTGGijw

#Epigenetics #MAT2A #Atherosclerosis

---
High-resolution insights without cell sorting; https://t.co/WmSYDGXnzb https://t.co/Qle7PCOBbO

0

8

1

2

636

rei @neo3v4

over 1 year ago

capek uji suku ke n, uji my will to live #itb #itbgirls #mat2A

1

7

4

1

842

Insilico Medicine

@InSilicoMeds

over 1 year ago

NEW Video 📽️ Synthetic Lethality Webinar and Hot Assets: #MAT2A and #PRMT5 Inhibitors Explore our latest insights in synthetic lethality in this webinar hosted by Keith Mikule and Sean Cullen from our asset BD team. This informative webinar outlines the concept of synthetic lethality in oncology as it applies to drug development. Our colleagues describe the promising PRMT5/MAT2A pathway and outline how small inhibitors against these targets have begun to yield great promise for tumors with loss of MTAP, which encompass around 15% of all solid tumors. They also touch on Insilico Medicine’s internal programs for both MAT2A (Phase 1) and PRMT5 (IND enabling). Watch it here. Check out the latest video here: https://t.co/4nVky9msbC

2

3

0

876

Aakash Desai @ADesaiMD

over 1 year ago

🚨Phase 1 #MAT2A inhibitor trial @NatureComms 🌟 🔹 AG-270 in advanced malignancies (n=40) 🔹 Grade 3 TRAEs in 15% (mostly lab abn) 🔹 2 PRs, 5 SD ≥16 weeks 📊 🔹 Proof-of-mechanism for MAT2A inhibition 💡 @OncoAlert https://t.co/xmZOQ63iqy

ADesaiMD's tweet photo. 🚨Phase 1 #MAT2A inhibitor trial @NatureComms 🌟
🔹 AG-270 in advanced malignancies (n=40)
🔹 Grade 3 TRAEs in 15% (mostly lab abn)
🔹 2 PRs, 5 SD ≥16 weeks 📊
🔹 Proof-of-mechanism for MAT2A inhibition 💡
@OncoAlert https://t.co/xmZOQ63iqy https://t.co/hHhEP4M4sO

0

3

2

1

1K

Kyosuke Seguchi, M.D.

@kyosuke_seguchi

about 2 years ago

I will present the prognosis of MTAP loss and the efficacy of ICIs in advanced solid tumors during the Basic Science & TR mini-oral session at ESMO on Monday, September 16th. The session is scheduled for 8:30 AM in Hall 5, Valencia. #ESMO2024 #MTAP #PRMT5 #MAT2A

1

10

4

3

2K

Ruven27

@Ruven27

about 2 years ago

$IDYA Citi Reiterates Buy Rating; PT $60 Citi's US Focus List #MAT2A $XBI Ideaya

0

5

3

1

1K

Insilico Medicine

@InSilicoMeds

over 2 years ago

Announcing FDA IND approval for Insilico's potentially best-in-class #AI-designed #MAT2A inhibitor, ISM3412. MAT2A is a promising target for MTAP-deleted #cancers, found in 15% of all cancers. More in @GENbio on the race to develop new treatments: https://t.co/2iB1xohESG

0

45

12

7

5K

Pengyu Yang @Pengyu19

over 4 years ago

Leveraging Structure-Based Drug Design to Identify Next-Generation #MAT2A Inhibitors, Including Brain-Penetrant and Peripherally Efficacious Leads https://t.co/nbBlsJg7CJ

0

1

0

1

0

J. Am. Chem. Soc. @J_A_C_S

almost 5 years ago

Mechanism of Triphosphate Hydrolysis by Human MAT2A at 1.07 Å Resolution @EinsteinMed #MAT2A #triphosphate #structuralbiology https://t.co/2L6zCOe6Fd

0

5

0

Gene Of The Day @GeneOfTheDay

about 7 years ago

Today’s #GeneOfTheDay is #Mat2a. Human diseases associated with this gene include Familial Thoracic Aortic Aneurysm And Aortic Dissection. Mice with this gene inactivated exhibit decreased prepulse inhibition and increased startle reflex: https://t.co/jPB10bgiWX